Research To Practice | Oncology Videos

Latest Episodes:

Mantle Cell Lymphoma | What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma Oct 19, 2023

Show notes

Featuring perspectives from Dr Toby A Eyre and Dr Brad S Kahl, including the following topics:

Introduction: Mantle Cell Lymphoma (MCL) and the General Medical Oncologist (0:00)
Sequencing of Therapy for MCL: 2009-2025 (11:19)
Cases and Questions from the Community (36:44)
Case: A man in his early 80s with relapsed/refractory MCL with "brain fog" on zanubrutinib — Zanetta S Lamar, MD (56:07)

CME information and select publications

Multiple Myeloma | Oncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology Conferences Oct 18, 2023

Show notes

Featuring an interview with Dr Joseph Mikhael, including the following topics:

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy for newly diagnosed multiple myeloma (MM) (0:00)
KRd versus elotuzumab and KRd for transplant-eligible patients with newly diagnosed MM (10:47)
Subgroup analysis of patients with 1q21 and other cytogenetic abnormalities in the Phase III IKEMA and ICARIA-MM studies (15:12)
Results with ciltacabtagene autoleucel among patients with relapsed/refractory (R/R) MM in the CARTITUDE-1 study (26:59)
CARTITUDE-4 study: Ciltacabtagene autoleucel in earlier lines of treatment for patients with lenalidomide-refractory MM (34:56)
KarMMa-3 trial: Idecabtagene vicleucel for patients with R/R MM (44:20)
GPRC5D-targeted CAR (chimeric antigen receptor) T-cell therapy for patients with R/R MM (49:09)
Efficacy of teclistamab for R/R MM in the MajesTEC-1 trial (53:45)
Efficacy of elranatamab for R/R MM in the MagnetisMM-3 trial (58:43)
Efficacy of linvoseltamab for R/R MM in the LINKER-MM1 trial (1:02:01)
Talquetamab for patients with R/R MM in the MonumenTAL-1 trial (1:04:16)
Future directions in the first-line management of MM (1:06:03)
Strategies to improve diversity and inclusion in clinical trials (1:10:53)

CME information and select publications

Lung Cancer | John V Heymach, MD, PhD Oct 16, 2023

Show notes

Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 2: Novel Approaches to Adjuvant Treatment for Localized NSCLC

CME information and select publications

Lung Cancer | Jamie E Chaft, MD Oct 16, 2023

Show notes

Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 1: The Evolving Role of Neoadjuvant Therapy for Localized Non-Small Cell Lung Cancer (NSCLC)

CME information and select publications

Lung Cancer | Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer Oct 16, 2023

Show notes

Featuring perspectives from Dr Jamie Chaft and Dr John V Heymach, including the following topics:

Introduction: Patient Involvement in Adjuvant and Neoadjuvant Treatment Decisions (0:00)
Targetable Treatment for Localized Disease (11:49)
Immunotherapy for Localized Disease (35:57)

CME information and select publications

Pancreatic Cancer | Oncology Today with Dr Neil Love: Management of Metastatic Pancreatic Cancer with Dr Michael Pishvaian Oct 13, 2023

Show notes

Featuring an interview with Dr Michael Pishvaian, including the following topics:

Importance of next-generation sequencing as part of the diagnostic workup for metastatic pancreatic cancer (0:00)
Optimal treatment selection for patients with germline BRCA mutation-positive pancreatic cancer (3:32)
NAPOLI-3 Phase III trial of liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) versus gemcitabine/nab paclitaxel for treatment-naïve metastatic pancreatic ductal carcinoma (5:48)
Perspectives on the comparative efficacy and tolerability of 2-drug and 3-drug treatment regimens in the metastatic setting; perioperative versus adjuvant therapy in locally advanced disease (9:22)
Novel treatment approaches for pancreatic cancer — zolbetuximab, tumor treating fields and intra-arterial gemcitabine (14:35)
Role of radiation therapy in the management of pancreatic cancer; early-phase data with novel antibody-drug conjugates (22:14)
Selection of second-line therapy for metastatic pancreatic cancer (26:15)
PARP inhibition for the treatment of pancreatic cancer (32:27)
Investigational approaches for the treatment of KRAS mutation-positive pancreatic cancer (48:50)
Vaccine-based treatment approaches under development for pancreatic cancer; palliative care strategies (52:04)

CME information and select publications

Non-Hodgkin Lymphoma | Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar Oct 12, 2023

Show notes

Featuring an interview with Dr Matthew Matasar, including the following topics:

Rationale for the evaluation of anti-CD20 x CD3 bispecific antibodies in the treatment of non-Hodgkin lymphoma (NHL) (0:00)
Incidence, severity and time course of cytokine release syndrome, neurotoxicity/ICANS and other adverse events associated with bispecific antibodies; recommended mitigation and management protocols (4:39)
Activity of and similarities and differences among the various bispecific antibodies for NHL (12:20)
Eligibility, efficacy and durability of response with mosunetuzumab, glofitamab, epcoritamab and odronextamab; ongoing and planned evaluations of bispecific antibodies alone and in combination with other systemic therapies (19:18)
Optimal integration of bispecific antibody platforms into treatment algorithms for patients with NHL (32:12)
Emerging results with bispecific antibodies for mantle cell lymphoma and chronic lymphocytic leukemia (41:51)

CME information and select publications

Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 1 of a 4-Part Series Oct 10, 2023

Show notes

Featuring perspectives from Dr Kathleen N Moore, including the following topics:

Introduction: SOLO-1 Trial (0:00)
Case: A woman in her mid 50s with a germline BRCA1 mutation who received IV/IP chemotherapy followed by olaparib maintenance experiences disease recurrence — Neil Morganstein, MD (15:58)
Case: A woman in her late 50s with a germline BRCA2 mutation undergoes surgery and chemotherapy for Stage II high-grade serous ovarian cancer (HGSOC) — Kellie E Schneider, MD (24:38)
Case: A woman in her late 70s with a somatic BRCA2 mutation and Stage IVB HGSOC who experienced disease progression on the placebo arm of the PRIMA trial and recurrence in 2019 receives liposomal doxorubicin/carboplatin and maintenance niraparib — Karim ElSahwi, MD (30:37)
Case: A woman in her early 50s presents with recurrent BRCA wild-type (WT), homologous recombination deficiency (HRD)-negative clear cell ovarian cancer after interval debulking surgery — Dana M Chase, MD (35:16)
Case: A woman in her early 60s with BRCA WT, HRD-negative, folate receptor alpha-positive ovarian cancer experiences primary disease progression on neoadjuvant carboplatin/paclitaxel and receives mirvetuximab soravtansine — Priya Rudolph, MD, PhD (46:49)
Investigator Survey (58:37)

CME information and select publications

Multiple Myeloma | What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma (Companion Faculty Lecture) Oct 09, 2023

Show notes

Featuring a slide presentation and related discussion from Dr Philippe Moreau, including the following topics:

General overview of anti-CD38 antibodies in therapy for multiple myeloma (MM) (0:00)
Anti-CD38 antibodies as part of first-line therapy for transplant-ineligible patients with MM (2:35)
Quadruplet versus triplet induction regimens with anti-CD38 antibodies for newly diagnosed, transplant-eligible patients with MM (7:44)
Clinical trial data with anti-CD38 antibodies for patients with MM at first relapse (13:02)
Treatment options for patients with MM at second relapse and beyond (18:09)
Subcutaneous formulations of daratumumab and isatuximab; CD38 as a target for other therapeutic strategies (21:00)

CME information and select publications

Multiple Myeloma | What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma Oct 09, 2023

Show notes

Featuring an interview with Prof Philippe Moreau, including the following topics:

Perspectives on efficacy outcomes with and toxicity profiles of daratumumab and isatuximab (0:00)
Selection of an anti-CD38 antibody for initial treatment of multiple myeloma (MM) (7:28)
Approach to maintenance therapy for transplant-eligible patients with MM (15:47)
Management of MM in older patients; treatment approaches for t(11;14) MM (22:47)
Management of relapsed/refractory MM (29:49)
Management of anti-CD38 antibody-associated side effects (35:45)
Other relevant clinical scenarios in MM — Plasma cell leukemia, smoldering myeloma (41:19)
Perspectives on the future landscape of up-front treatment for MM (45:02)

CME information and select publications